A Study of DS-1471a In Subjects With Advanced Solid Tumors
← catalyst calendarSponsored by Daiichi Sankyo Co., Ltd. (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
17actual
Sites
5
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated by the sponsor due to a business decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-04 | actual | When the study began enrolling |
| Primary completion | 2025-07-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-29 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Intervention
- Drug: DS-1471a
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose-limiting Toxicities Following Treatment With DS-1471a (Dose Escalation)
measured Cycle 1: Baseline up to Day 28 (each cycle is 28 days)
Number of Participants With Treatment-emergent Adverse Events Following Treatment With DS-1471a (Dose Escalation and Expansion)
measured Baseline up to 60 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed